To combat this, many groups have expanded on novel immunotherapeutic target discovery with antigens such as glypican-2 (GPC2), New York oesophageal squamous cell carcinoma 1 (NY-ESO-1), B7-H3 (also known as CD276), neural cell adhesion molecule (NCAM)(also known as CD56), L1 cell adhesion molecule (L1CAM) (also known as CD171), preferentially expressed in melanoma antigen (PRAME) and programmed death-ligand 1 (PD-L1) (also known as CD274) showing more promise in the neuroblastoma field (reviewed extensively in [4,6]). Here, CD276 is linked to neuroblastoma.